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Background: The successful diffusion of new drugs is crucial for both pharmaceutical companies and patients—and
of wider stakeholder concern, including for the funding of healthcare provision. Micro-level characteristics
(the socio-demographic and professional characteristics of medical professionals), meso-level characteristics
(the prescribing characteristics of doctors, the marketing efforts of pharmaceutical companies, interpersonal
communication among doctors, drug attributes, and the characteristics of patients), and macro-level characteristics
(government policies) all influence the diffusion of new drugs. This systematic literature review examines the micro- and
meso-level characteristics of early prescribers of newly introduced drugs. Understanding the characteristics of early
adopters may help to speed up the diffusion process, promote cost-efficient prescribing habits, forecast utilisation,
and develop targeted intervention strategies.
Methods: The PubMed and Scopus electronic databases were chosen for their extensive coverage of the pertinent
literature and used to identify 205 potentially relevant studies by means of a four-layered search string. The 35 studies
deemed eligible were then synthetized carefully and critically, to extract variables relevant to this review.
Results: Early adoption of new drugs is not a personal trait, independent of drug type, but early adopters share both
micro- and meso-level characteristics. At prescriber level, doctors’ interest in particular therapeutic areas, participation in
clinical trials, and volume of prescribing—either in total or within the therapeutic class of the new drug—increase the
likelihood of early adoption. The marketing efforts of pharmaceutical companies and doctors’ professional and social
interactions leading to prescribing contagion are very powerful predictors of new drug uptake. At patient level, doctors
with younger patients, patients with higher socioeconomic statuses and/or patients with poorer health statuses are more
inclined to prescribe new drugs early. In contrast, the socio-demographic characteristics of prescribers and many
practice-related factors play little role in the adoption process.
Conclusions: The most powerful predictors of new drug uptake include the doctors’ strong scientific commitment,
high prescribing volume in total or in within the therapeutic class of the new drug, high exposure to marketing, and
intense communication with colleagues.
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In most industrialised countries, drug expenditure as a
percentage of overall healthcare cost is increasing rapidly.
Changing demographics—ageing populations with in-
creased morbidities—and a rise in the number of drugs
per patient contribute obviously to growing prescrip-
tion costs. However, the key factors in rising drug
expenditures are the greater variety and availability of
new, expensive drugs and the higher relative costs of
pharmaceuticals [1,2].
Innovation and the successful diffusion of new drugs
are critical for the financial performance of pharmaceut-
ical companies—as well as the health of patients. New
drug diffusion is determined mostly by the strategies of
pharmaceutical companies, government policies, as well
as the behaviour of medical professionals. This article
concentrates on the last, through a systematic review of
the literature using behavioural (prescribing) data.
Although doctors consider each new drug on its in-
dividual merits, some seem more predisposed to adopt
new drugs than others. This article sets to analyse
whether early prescribers of newly marketed drugs are
consistently associated with potential prescriber, prac-
tice, and patient characteristics—as well as with new
drug attributes. To the author’s knowledge, this article
is a pioneering attempt at documenting the early
adopter characteristics identified by empirical research,
thus bringing a valuable contribution to the literature
on new drug diffusion. To this end, it synthetizes find-
ings across various countries, drug types, and pre-
scribers—it does not analyse specific drugs or certain
specialist groups in isolation.
At micro level, this article sets to analyse the socio-
demographic and professional characteristics of early
prescribers of newly marketed drugs—as compared to
majority and late prescribers. These micro-level charac-
teristics may be defined as characteristics related to the
doctors’ personality. At meso level, this article aims to
consider quantitatively measurable patient, practice, and
drug characteristics and analyse the roles marketing
and interpersonal communication play in the adoption
process. These meso-level characteristics describe the
working environment in which the doctors practice.
At macro level, government agencies and health care or-
ganizations are also major influencers as they set the regu-
latory environment with which pharmaceutical companies
and doctors have to cope. While acknowledging the cru-
cial role of macro-level factors in making new medicines
available, this article does not aim to review their influence
on new drug diffusion.
In this review the terms ‘new drug’ and ‘newly mar-
keted drug’ are used as synonyms and refer to a drug
that has been recently approved and introduced to the
market. New drugs might be highly innovative drugs—first-in-class drugs with new ATC (Anatomical Thera-
peutic Chemical Classification System) codes. New
drugs might also be me-too or follow-on drugs, which
enter the market in an already existing drug class and
are chemically very similar to already approved drugs.
In this review only highly innovative drugs are consid-
ered as pharmaceutical innovations.
Knowing which factors determine new drug uptake is
important for several reasons.
First, it might help speeding up diffusion. Although
companies come up each year with several new drugs
[3], their implementation is often delayed [4]. Where
new drugs expand therapeutics in areas of yet unmet
clinical need, accelerated adoption benefits both medi-
cine and society. If budget allows, new drugs should be
offered fast and homogeneously to the population in
need—a strategy built upon the key determinants of new
drug diffusion is required.
Second, it might help promoting cost-efficiency. Health-
care systems worldwide operate with limited financial
resources. If new newly marketed drugs are cost effi-
cient —the health status of patients is either maintained
at a lower cost, or a better health status is achieved from
the same budget— policy makers should encourage the
adoption of these cost efficient new drugs to assure the
widest accessibility to the particular therapy from the
limited healthcare budget [5]. The identification of key
determinants might support policy makers in this effort.
Third, it might help forecasting utilisation. Accurate
prediction is important not only for pharmaceutical
companies, but also for healthcare professionals and pol-
icy makers in charge of healthcare budget planning.
Fourth, it might help developing targeted detailing and
continuing medical education (CME). Where the adop-
tion of new prescription drugs varies among doctors,
there is significant potential for targeted pharmaceutical
company intervention and CME. Distinguishing between
doctors who prescribe new drugs early and those who
prescribe them late or never enables targeted interven-
tion through relevant, tailored information—as well as
economies of both time and money. In general, detailing
and CME should promote appropriate use of new drugs,
through prescription of the most efficient/least expen-
sive available alternatives [6].
This review is structured into five sections. Following
this ‘Background’, the second section (‘Methods’) pre-
sents the research strategy adopted to identify relevant
literature. The third section (‘Results’) describes the
characteristics of the eligible studies, and summarises
the research evidence. At prescriber level, this section
discusses characteristics of early adopters with respect to
socio-demography, scientific orientation, prescribing pat-
tern, exposure to marketing, and social interaction. The
influence of certain practice characteristics, drug attributes,
Lublóy BMC Health Services Research 2014, 14:469 Page 3 of 25
http://www.biomedcentral.com/1472-6963/14/469and patient-related factors on the adoption of newly mar-
keted drugs is also discussed in this section. The fourth
section (‘Discussion’) elaborates on the variables that pro-
duce consistent prediction of new drug uptake and sug-
gests directions for future research. The fifth section
(‘Conclusions’) summarises the research findings.
Methods
Search strategy and literature selection
This review focuses on literature assessing the prescrip-
tion of new medicines in either primary or secondary
care, with time, geography, and language of no specific
interest. The databases used were PubMed and Scopus,
and the search was conducted on 24 July 2013. All arti-
cles added to the databases until this date were included.
PubMed contains journal citations and abstracts for
biomedical literature from around the world, whereas
Scopus is the largest all-science database of peer-
reviewed research literature. The final search string was
determined after an initial broad search of the literature
using the keywords summarised by category in Table 1.
Studies were retrieved if either abstract or main text in-
cluded at least one keyword from each of the four major
categories. Their bibliographies—as well as relevant
literature reviews—were rigorously checked to identify
further studies. Citations of these studies were also
screened, through Google Scholar, with the same aim.
Studies were downloaded and screened for eligibility
along four criteria:
1. The study was published in a peer-reviewed journal.
2. The study evaluated factors affecting the uptake of
new medicines.
3. The study used prescription data from national
registries, pharmacy offices, or administrative claims
databases. Prescription data reflect the realities of
prescribing decisions—including the influences
associated with marketing activities (sales
representatives, advertisements, and patient
requests), evidence bases (peer-reviewed journals
and scientific meetings), peer pressures, andTable 1 Summary of keywords for the search strategy
Category Keywords
Object (abstract) new ATC, new drug(s), new medicine(s), new
medication, new substance(s)
Process (abstract) adopt(ed), adoption, diffuse, diffusion, uptake
Actor (abstract) doctor(s), general practitioner(s), GP(s),
physician(s), specialist(s), SP(s)
Data and method (text) claim(s), county, logit, nation, odds, population,
prescribing, prescription(s), quantitative(ly),
region, registry, regression, survival
In alphabetical order, by keyword. The search strings are available from author
on request.regulatory environments. Prescription data also
reflect patient characteristics as well as the personal
and behavioural traits of prescribing doctors.
Qualitative study designs (interviews, focus groups,
surveys, and mail questionnaires) were not eligible
for inclusion, since methodological drawbacks call
their findings into question. A retrospective study
based on self-report is at risk of recall and social
desirability biases—rather than what actually occurs
in practice, surveys and interviews may simply
capture normative responses and expressed attitudes
[7-9]. Decision making may involve subconscious
factors or factors which prescribers—for whatever
reasons—choose not to disclose [10]. To avoid
screening numerous studies designed qualitatively,
methodology-related keywords were added to
the search strategy. Some studies complemented
prescription data with survey data [7,11-15]—
nevertheless, since the act and timing of adoption are
free of recall bias, they were deemed eligible for review.
4. The study concerned at least one significant prescriber
or practice characteristic. Studies solely concerning
patient characteristics—such as age, gender, and
comorbidity—or drug characteristics—such as safety
and efficacy—were excluded from this review.
Data extraction
An Excel database was created to chart the characteristics
of the eligible studies and the variables relevant to this re-
view—it included information on the journal where the
study was published, study population, country where the
study was conducted, analytical method, and the variables
the study assessed for impact on new drug uptake. The
charted variables were grouped into four categories—pre-
scriber, practice, patient, and drug characteristics. Stand-
ard database functions were used for analysis.
Results
Search flow
As Figure 1 shows, 178 studies were removed from the
initial 205—54 on grounds of duplication and 124 be-
cause at least one of the four eligibility criteria was not
met—and 8 were added, following identification through
bibliographies and citations. Table 2 summarises the
remaining 35 eligible studies [1,5-7,11-41] in terms of lo-
cation and size of the sample population, type and num-
ber of study drugs, methodology, and factors that might
influence new drug uptake.
Study characteristics
Sample populations
The 35 eligible studies were all conducted in devel-
oped countries—mostly in North America (17 studies)
[1,6,7,12-15,19,26-30,33,35,38,39] and North-Western
205 potentially relevant studies
identified in the PubMed and 
Scopus electronic databases
54 studies removed on grounds of 
duplication
151 potentially relevant studies 
screened (on abstract)
35 eligible studies downloaded
100 studies removed because at least one of 
the four eligibility criteria was not met (84 
studies did not meet criterion 2 and 16 did 
not meet criterion 3)
51 potentially relevant studies 
screened (on full text)*
24 studies removed because at least one of 
the four eligibility criteria was not met (13 
studies did not meet criterion 2, 4 did not 
meet criterion 3, and 7 did not meet 
criterion 4)
8 studies added following identification 
through bibliographies and citations
Figure 1 Flow diagram of the search strategy. *The full texts of the 51 potentially relevant studies were assessed by Ágnes Lublóy (100%) and
Gábor Benedek (12%). The colleagues agreed on all studies reviewed together.
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studies were conducted in the US [7,12-15,19,26-30,33,
38,39], four in Denmark [20-22,40], three each in Canada
[1,6,35] and Spain [16,24,25], two each in the Netherlands
[11,23] and Taiwan [36,37], and one each in Australia [17],
Finland [32], Germany [41], Ireland [18], Sweden [5], and
the UK [34], while one study [31] covered ten developed
countries—Belgium, Canada, France, Germany, Italy,
Japan, the Netherlands, Spain, the UK, and the US.
The sample populations varied greatly, in both unit of
observation and size. In one study [31], the unit of ob-
servation was the country—in five others [5,16,20,21,37],
the healthcare provider, ranging from 32 healthcare
centres [16] to 191 practices [20,21], with a mean of 146
and one study not disclosing the number [37]. However,
doctors were the unit of observation for 29 [1,6,7,11-15,
17-19,22-30,32-36,38-41] of the 35 eligible studies—nine
studies observed general practitioners (GPs) [7,11,15,17,
18,22,23,34,40], three specialists (SPs) [14,25,36], and 17
both [1,6,12,13,19,24,26-30,32,33,35,38,39,41]. The sam-
ple populations ranged from 68 [22] to 74,075 doctors
[39], with a median of 770.Study drugs
The study drugs covered a wide range—antibiotics, cardio-
vascular drugs, coxibs, antihypertensives, and antidepres-
sants, for example. Ten studies used the prescription data
for one drug/therapeutic class [5,7,11-13,15,36,38,39,41],
eight studies used the prescription data for two to five
drugs [6,14,17,22,23,32,35,40], six for six to ten drugs
[18,25,26,30,33,37], and 11 for more than ten drugs
[1,16,19-21,24,27-29,31,34]—50 new drugs [16] and 72
new compounds of varying therapeutic novelty [27]
were the maxima. Twenty two studies assessed highly
innovative drugs [5,6,11,13,14,17,20-22,26,27,29-33,35-
38,40,41], three me-too drugs [7,12,15] and ten both
[1,16,18,19,23-25,28,34,39].
Methods
Eight studies used simple statistical methods [6,7,17,
20,26,31,34,41]—comparison of means or association or
correlation analyses, for example. Other eight studies—
published mostly in the 2010s—used either discrete-
time hazard models or very similar survival analyses
[12,13,15,18,25,33,36,38]. However, the most popular
Table 2 Key characteristics of the eligible studies




32 healthcare centres, 313321
inhabitants, Spain
50 new drugs multiple linear regressions Practice characteristics: size (number of doctors and number of patients),
location (urban or rural), number of years functioning as a primary care
centre, pharmaceutical expense per secured patients, number of consultations
per doctor
Patient characteristics: proportion of patients in pension
Behan et al.
2005 [17]
126991 inhabitants, 134 full-time
equivalent GPs, Australia








616 GPs and all their prescriptions,
Ireland
6 new drugs, from 6 therapeutic
classes
survival analysis Prescriber characteristics: age, portfolio width, savings made from meeting
prescribing targets, GP being an early adopter in at least one of the other five
study drugs
Practice characteristics: employee composition* (practice with nurse, practice with
secretary), practice with in-house dispensary, location (urban or rural)
Drug/market characteristics: time-variant percentage of GPs who have adopted
the study drug
Coleman
et al. 1966 [7]
125 GPs (prescriptions and
interviews) and 103 SPs (interviews),
four small cities in Illinois, US
1 new drug (tetracycline, a broad-
spectrum antibiotic)
elementary statistics Prescriber characteristics: age, prescribing volume in the therapeutic class of the
new drug, speciality, number of contacts with drug representatives, number of
professional journals read, number of pharmaceutical house organs read,
number of speciality meetings attended, number of non-speciality meetings
attended, number of hospital meetings attended, number of county medical
society meetings attended, perceived scientific orientation, social position in ad-
visor, discussion, and friendship networks
Practice characteristics: type (solo or group/partnership)
Note: The survey questionnaire resulted in a very large number of variables—





4216 doctors, US 38 new compounds analysis of covariance
(ANCOVA) model
Prescriber characteristics: gender, age, board certification, hospital affiliation, type




191 practices, 470000 inhabitants,
Denmark




Practice characteristics: type (solo or group/partnership)




191 practices, 470000 inhabitants,
Denmark
14 new drugs, grouped in 4
categories
multiple linear regressions Practice characteristics: prescribing volume within the therapeutic class of the
new drug, number of patients eligible for the new drug, prescribing volume




68 GPs, Denmark 2 new drug groups (COX-2 and AT-II) univariate and
multivariate linear
regressions
Prescriber characteristics: perceived scientific orientation, perceived need for




86 GPs, 13997 patients, the
Netherlands
5 new drugs, from 5 therapeutic
classes
logistic multilevel model Prescriber characteristics: quality of pharmacotherapy audit meetings (PTAMs),
PTAM composition (number of pharmacists



















Table 2 Key characteristics of the eligible studies (Continued)
García et al.
2000 [24]
74 GPs and SPs (paediatrics), Spain 28 new drugs, 10 with therapeutic




Prescriber characteristics: age, gender, speciality, type of contract (permanent
or temporary), number of workplaces, drug expenditure captured by the
deviation from the district’s mean
Practice characteristics: management (reformed or non-reformed), region
Garjón et al.
2012 [25]
1248 doctors, Spain 8 new drugs, suitable for both
primary and secondary care
survival analysis Prescriber characteristics: speciality
Drug characteristics: therapeutic novelty
Glass 2003
[26]
1876 doctors, US new drugs for the outpatient








2108 clinical trial investigators, US 72 new compounds multiple linear regressions Prescriber characteristics: gender, age, board certification, hospital affiliation, per
cent of working hours spent in a hospital setting, clinical research experience
(total number of clinical studies, number of clinical studies conducted for the
sponsoring company, number of clinical studies conducted in the therapeutic
class of the new drug, number of clinical studies with the compound), relative
grant amount received by investigator, pre-launch prescribing volume, pre-
launch prescribing volume in the therapeutic class of the new drug, pre-launch
prescribing of the sponsoring company’s products as a percentage of total pre-
scribing (company loyalty), market share of the sponsoring company 3 and 6
months post launch as percentage of total prescribing volume
Drug/market characteristics: therapeutic novelty, number of drugs tested for
the same indication, participation of a contract research organisation, market




3646 doctors, US 32 new drugs binomial logistic
regression
Prescriber characteristics: gender, age, board certification, speciality, clinical
investigation experience, hospital affiliation, pre-launch prescribing volume, pre-
launch prescribing volume in the same therapeutic class as the new drug, pre-
launch company loyalty
Drug characteristics: therapeutic novelty, marketing budget of the




2287 clinical trial investigators, US 38 new drugs ordinary least squares
(OLS) and binomial
logistic regression
Prescriber characteristics: gender, age, board certification, speciality, hospital
affiliation, percentage of working hours spent in a hospital setting, clinical
research experience (total number of clinical trials, total number of clinical
studies conducted, total number of clinical studies conducted for the sponsoring
company, total number of clinical studies conducted in the therapeutic class of
the new drug, total number of clinical studies conducted with the compound),
total pre-launch prescribing volume, pre-launch prescribing volume in the
therapeutic class of the new drug, pre-launch prescribing volume of sponsoring
company’s products, pre-launch prescribing volume of sponsoring company’s
products as a percentage of total prescribing (company loyalty)
Drug characteristics: market share of the new drug 12 months post launch,























484 phase IV clinical trial
investigators, US
new drugs for the outpatient
treatment of 8 disorders or diseases
binomial logistic
regression
Prescriber characteristics: gender, age, board certification, speciality, practice
type (office, hospital, academic medical centre, other), per cent of working
hours spent in a hospital setting, clinical research experience (number of
clinical trials conducted, number of clinical studies conducted for the
sponsoring company, number of clinical studies conducted in the same
therapeutic class as the new drug, number of clinical studies conducted with
the compound), relative grant amount received,
pre-study prescribing volume, pre-study prescribing volume in the same
therapeutic class as the new drug, pre-study prescribing volume of the new drug,
pre-study prescribing volume of sponsoring
company’s products, pre-study prescribing volume of sponsoring company’s
products as a percentage of total prescribing (company loyalty)
Drug characteristics: market share of the new drug in its therapeutic class 12
months post launch, revenue of the pharmaceutical company
Greving et al.
2006 [11]
70 GPs, 9470 hypertensive patients,
the Netherlands




Prescriber characteristics: use of commercial information, use of medical journals,
CME, use of other professional information, use of a prescribing decision
support system, personal involvement in PTAMs
Practice characteristics: type (solo or group/partnership), location (urban or
rural)
Patient characteristics: age, gender, number and type of comorbidities, referrals
to internist/cardiologist




10 developed countries drugs introduced in the last 5 years descriptive statistics Prescriber characteristics: nationality
Groves et al.
2010 [6]
925 doctors and all their
prescriptions, Canada
4 new drugs (COX-2 inhibitors) correlation analysis with t-
tests
Prescriber characteristics: gender, age, birthplace, speciality, training location
(domestic or overseas qualification), professional age, prescribing volume of four
related drugs





2558 doctors, 507262 prescriptions
from the same therapeutic class,
Finland




Prescriber characteristics: gender, professional age, speciality








Prescriber characteristics: gender, age, speciality, hospital affiliation*, prescribing
volume in the same therapeutic class as the new drug, training location
(domestic or overseas qualification,
top- or non-top-25 medical school)
Practice characteristics: type (solo or group/partnership)




3346 GPs, England 27 new drugs descriptive statistics Prescriber characteristics: gender, number of treatments, professional age, training



















Table 2 Key characteristics of the eligible studies (Continued)
Iyengar et al.
2011 [12]
185 doctors, US 1 new drug, third entry in the




Prescriber characteristics: speciality (GP or SP), number of patients, referral to
other doctors, prescribing volume in the same therapeutic class as the new drug,
self-reported leadership*, detailing, indegree centrality (referral, discussion, and
total network), outdegree centrality (referral, discussion, and total network),
peer influence through adoption and usage*
Practice characteristics: type (solo or group/partnership), type of hospital




12 million patients and 2000
doctors, Canada




Prescriber characteristics: age, gender, speciality*, professional age, training
location, hospital affiliation*
Practice characteristics: type (solo or group/partnership)
Patient characteristics: age, gender, neighbourhood income quintile*,
prescription reimbursement status, presence of chronic conditions
Lin et al.
2011 [36]
155 SPs (psychiatry) affiliated with
12 healthcare centres, Taiwan





Prescriber characteristics: age, gender, speciality (in depressive disorder), hospital
experience (number of current workplaces), outpatient services (number of
visits), peers’ adoption ratio, opinion leaders’ adoption ratio, (dis)similarities with
adopting peers’ age, gender, and tenure, SNRI proportion (past experience and
preference for SNRI)






7 new drugs (oral hypo-glycemic
agents, for treatment of diabetes)
logit model Practice characteristics: market share (number of outpatient visits), ownership*
(public or private not-for-profit or private for-profit), accreditation level (clinic,
academic medical centre, metropolitan hospital, or local community hospital),
location
Patient characteristics: age, gender, disease severity, number of prescriptions per
visit









Prescriber characteristics: speciality, prescribing volume in the same therapeutic
class as the new drug, number of detailing visits, number of medical meetings
and events, number of patient requests made to doctors, number of peers in
geographic proximity who had already adopted the new drug
Drug characteristics: journal advertising, linear time trend
Patient characteristics: median age of people in the community, average




466 doctors, Manhattan (New York
City), US




Prescriber characteristics: contemporaneous effect of detailing, accumulated stock
of detailing, accumulated stock of sampling, contagion measure (number of
adopting doctors in geographic proximity)
Drug characteristics: aggregate marketing expenditure (direct-to-consumer



















Table 2 Key characteristics of the eligible studies (Continued)
Mark et al.
2002 [14]
187 doctors, 752 patients,
prescriptions from medical records,
US





Prescriber characteristics: age, gender, board certification*, number of patients*,
number of contacts with pharmaceutical representatives*, attendance on
professional meetings*, preference for atypical initial treatments, preference for
atypical treatments for nine different conditions*, percentage of patients
influenced by individual medication costs
Practice characteristics: location
Patient characteristics: age, gender, race/ethnicity, education, marital status,
insurance status, first onset of the disorder, diagnosis*, symptoms, hospitalisation




74075 doctors, US 1 new drug, within a well-established
therapeutic area, and 2 older drugs
dynamic fixed effects
distributed lag regression
Prescriber characteristics: speciality*, detailing volume, sampling volume,




73547 doctors, 32011 patients,
Sweden
1 new drug (rosuvastatin, for




Practice characteristics: ownership (public or private), proximity to SPs, location
(urban or rural), size (prescribing volume)





319 GPs, 193876 prescriptions,
Denmark
5 generically new compounds multiple logistic
regression
Prescriber characteristics: gender, age
Practice characteristics: type (solo or group/partnership), size (number of patients),
number of consultations per patient, number of telephone consultations per
patient, number of home visits per patient, number of procedures performed
per patient, number of laboratory tests performed per patient
Ruof et al.
2002 [41]
72 GPs, 28 SPs (neurology),
Germany




Prescriber characteristics: speciality (GP or neurologist)
Drug characteristics (perceived): safety, efficacy, life quality improvement,
nursing home admission delayed, budgetary impact
Tamblyn
et al. 2003 [1]
1661 doctors, 669867 elderly
patients, Canada





Prescriber characteristics: gender, speciality, professional age*, training location
Practice characteristics: location (urban or rural), referral rate to SPs who prescribe
drugs in the same therapeutic class as the new drug*, size
Drug characteristics: detailing (minutes), advertising (pages)





121 GPs, four small cities in Illinois,
US




Prescriber characteristics: professional age, number of journals read, position,
scientific orientation, status (number of nominations received as advisor or
discussant—2 contagion variables to capture word of mouth operating over
direct ties and 2 contagion variables to capture competition for status
between structurally equivalent doctors
Drug characteristics: seasonal effect, depreciation-adjusted stock of marketing
effort by the first entrant, depreciation-adjusted stock of marketing effort by
the two subsequent entrants
In alphabetical order, by first author. Variables in italics without asterisk: significant impact on new drug uptake in all specifications of the study. Variables in italics with asterisk: significant impact on new drug uptake
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variables were logistic and linear regressions, used in
11 [1,5,11,14,23,28-30,35,37,40] and respectively eight
studies [16,19,21,22,24,27,32,39].
Dependent variables
The dependent variables under consideration varied
greatly, with some studies focusing on either prescriber
[17,22,23,26,31,34,39] or practice [16,21] characteristics,
whilst others assessing two or more categories of vari-
ables [1,5-7,11-15,18-20,24,25,27-30,32,33,35-38,40,41]—
prescriber and practice characteristics were the most
common such combination. On average, the studies in-
cluded nine dependent variables. Table 3 summarises the
dependent variables found significant in at least one of
the 35 eligible studies, whereas the last column of Table 2
details all the inputted variables—their number high-
lights the complexity of new drug diffusion.
Factors affecting new drug uptake
In both primary and secondary care, new drug diffusion
is subject to interacting influences. The idea that early
prescribers do not generally exist [20,35,40] does not ne-
cessarily mean that adoption of new drugs is random.
Rather, adoption varies across prescribers, with the pre-
scriber, patient, practice, and drug characteristics. The
35 eligible studies [1,5-7,11-41] identified several—partly
overlapping—characteristics that proved crucial in the
adoption process, and that predicted—seemingly consist-
ently—new drug uptake. This review will clearly indicate
the characteristics constant across drug types. However,
in a number of cases, there is contradiction within the
literature. Whilst some studies found one particular
variable significant, others found no evidence for the
predictive power of that variable. Also, reported coeffi-
cients between one particular variable and new drug up-
take were not always consistent in terms of sign. These
anomalies will also be clearly indicated in this review.
Prescriber characteristics
Twenty nine of the 35 eligible studies investigate at
least one prescriber characteristics [1,6,7,11-15,18,19,22-
36,38-41].
Socio-demographic characteristics
Nineteen of the 35 eligible studies investigate at least
one socio-demographic characteristics of prescribers
[1,6,7,14,15,18,19,24,27-36,40].
Gender (n = 15) [1,6,14,19,24,27-30,32-36,40]. Gender
played an influential role in the early adoption of new
drugs in seven [1,6,27,32-34,40] of the 15 studies—in the
other eight [14,19,24,28-30,35,36], the variable was not
significant. Where gender was found influential, male
prescribers were much more likely to adopt new drugsthan female prescribers, a finding consistent across drug
types. In a large-scale quantitative study of British doctors,
the first of its kind, Inman and Pearce [34] observed
that male doctors had much higher rates of new drug
utilisation than female doctors—in the group that pre-
scribed new drugs most heavily, women accounted for
only 9 per cent. Later studies came to similar conclusions
[1,6,27,32,33,40]. In contrast, Glass [27] found that women
were somewhat more likely than men to embrace new
drugs six months after launch, but not after just three.
Age (n = 14) [6,7,14,18,19,24,27-30,33,35,36,40]. Age
was associated with new drug uptake in nine studies
[6,7,18,27-30,33,35]. Seven of these found that early pre-
scribers were younger than the majority [7,18,27-30,33],
with younger doctors’ higher propensity for innovation
and older doctors’ more established prescribing practices
as the most likely explanations, whereas the other two
found that early prescribers were likely to be older
[6,35]. Five other studies found no correlation at all
[14,19,24,36,40].
Professional age (n = 5) [1,6,15,34,35]. Defined as the
number of years since graduation from medical school
[15,34], professional age can be proxied by the number
of years spent in practice [6,35]. Although professional
age evidently correlates highly with agea, its impact on
new drug uptake is less obvious—one study found no as-
sociation [35], two studies found significant positive as-
sociations [6,34], whereas two others found significant
negative associations [1,15]. However, positive associa-
tions were found in less powerful, bivariate analyses
[6,34]. In more powerful, multivariate analyses, similar
to studies assessing the impact of age on new drug up-
take, younger professional age was found favourable to
early adoption [1,15].
Training location (n = 5) [1,6,33-35]. So far, due to data
constraints, only five studies assessed the role of training
location in new drug uptake [1,6,33-35], and—with one
exception [6]—found it influential. From British [34] and
Northern American [35] perspectives, more new drugs
were prescribed by doctors with overseas qualifications
than by doctors with domestic qualifications. At the
same time, Huskamp et al. [33] reported that doctors
who had graduated from a top-25 medical school were
slower to adopt than others, with high-ranking medical
schools possibly more conservative than others in adopt-
ing new drugs and granting exposure to pharmaceutical
marketing. Also, Tamblyn et al. [1] found that doctors
who had graduated from the youngest medical schools
had higher relative rates of new drug use than others.
Number of current workplaces (n = 2) [24,36]. The two
studies led to ambiguous conclusions—García et al. [24]
found that doctors with more than one workplace
adopted new drugs earlier than others, whereas Lin et al.
[36] found the number of current workplaces irrelevant.
Table 3 Summary of characteristics influencing new drug diffusion
Prescriber characteristics
(micro- and meso-level)






Location (urban or rural) (3/7) Marketing budget of the
pharmaceutical company
assigned for the new drug (5/7)
Age (6/9)
Gender (7/15) Type (solo or group/partnership) (4/7) Overall acceptance (5/6) Gender (1/6)
Age ( 9/14) Size (2/6) Therapeutic novelty (2/3) Health (3/4)
Professional age (4/5) Ownership (private or public), management
(reformed or non-reformed), and orientation
(for profit or not for profit) (3/4)
Competition (1/1) Socioeconomic characteristics
(income, education, and health
insurance) (3/4)
Training location (4/5) Region (1/4) Marital status (1/2)
Number of current workplaces (1/2) Accreditation level (1/2)
Nationality (1/1) Diagnostic and therapeutic activities (2/2) Race/ethnicity (2/2)
Scientific orientation (micro-level) Employee composition (1/2)
Speciality (10/16) Other (2/2)
Hospital affiliation (4/8)
Board certification (2/6)
Clinical trial participation (3/3)
CME [continuing medical education]
and pharmacotherapy audit
meetings (PTAMs) (2/3)
Number of professional journals
read (2/3)
Perceived scientific orientation (2/3)




Prescribing volume in the
therapeutic class of the new
drug (10/11)
Total number of patients/
prescriptions (6/9)
Prescribing volume of drugs by the
same pharmaceutical company (4/4)
Portfolio width (1/1)








In brackets, the number of studies where the variable was found significant in the adoption process over the number of studies assessing the impact of the variable.
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of adoption was measured across nationalities found
that doctors in Italy, Germany, Spain, and the US were
more likely to prescribe products with new active chem-
ical entries than doctors in the other six countries underreview, Belgium, Canada, France, Japan, the Netherlands,
and the UK [31]. British doctors were found least likely
to prescribe new drugs—they relied on progressively
fewer active substances for a greater proportion of
their prescriptions.
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Twenty four of the 35 eligible studies access some as-
pects of prescribers’ scientific orientation [1,6,7,11-15,19,
22-30,32,33,35,36,39,41].
Speciality (n = 16) [1,6,7,12,13,24,25,28-30,32,33,35,36,
39,41]. Intuitively, doctors are likely to prescribe new
drugs in clinical and therapeutic areas where they feel
familiar or have special interests. Also intuitively, since a
significant amount of general practice prescribing is
hospital-initiated or hospital-led [42,43], SPs are likely to
influence new drug uptake among GPs, through advice
or example. There is a broad consensus in the literature
that new drugs diffuse into general practice in two
stages, with SPs as innovators and GPs as followers [44].
In line with this model, ten of the 16 eligible studies re-
ported faster adoption among SPs in secondary care
than among GPs in primary care, and found that spe-
cialisation in the therapeutic areas of newly introduced
drugs associated with adoption rate significantly and
positively [1,7,13,25,28,29,32,33,36,41]. For example,
Garjón et al. [25] analysed the diffusion of eight new
drugs suitable for common disorders in both primary
and secondary care concluded that SPs adopted new
drugs earlier than GPsb. There is also a broad consensus
in the literature that SPs adopt new drugs in their special-
ity earlier than GPs and other SPs, both of whom tend to
rely on norms—low prescribing proportions do not justify
high cognition time costs [33].
However, six of the 16 eligible studies came to different
conclusions [6,12,24,30,35,39]. Groves et al. [6] found that
GPs were more likely early prescribers than SPs. Kozyrskyj
et al. [35] found mixed evidence—in some cases, GPs
adopted new drugs earlier than SPs, whereas in others no
significant associations were observed. Four other studies
found no or weak associations between speciality and new
drug uptake [12,24,30,39].
Hospital affiliation (n = 8) [19,22,27-30,33,35]. Associ-
ation with an academic centre such as a university or a re-
search institute—through teaching, publishing, or holding
an academic appointment, for example—suggests a pro-
fessional orientation that may result in early adoption of
new drugs. However, hospital-affiliated doctors face for-
mulary restrictions.
In line with the heightened professional orientation
argument, two of the eight eligible studies found that
doctors in hospital settings adopted some new drugs
earlier than doctors with no hospital affiliation—two out
of four new drugs, according to Kozyrskyj et al. [35], and
two out of nine, according to Huskamp et al. [33]. In
contrast, four studies reported that office-based clinical
trial investigators were more likely to prescribe newly
marketed drugs than other doctors [19,27-29]. Moreover,
the longer doctors worked in hospitals, the less likely
they were to prescribe new drugs [19,29], not least dueto hospital formularies [28,29]. Two studies observed no
difference between hospital-affiliated and office-based
doctors [22,30].
Board certification (n = 6) [14,19,27-30]. In the US,
board certification quantifies on a voluntary basis doc-
tors’ mastery of the core body of knowledge and skills
in their chosen specialities at a specific time [45].
Board certification was found consistently associated
with adoption in two [19,28] of the six studies, but not
in the others [14,27,29,30].
Clinical trial participation (n = 3) [19,26,28]. Due to
proximity to research and understanding of the evidence
base, clinical trial participation increased early adoption
of new drugs and had a significant and positive impact on
subsequent prescribing in all eligible studies [19,26,28].
Other studies published within the same research frame-
work by Glass and colleagues provided further insight
into the new drug uptake of clinical trial investigators
[27,29,30]. As expected, participation in drug class clinical
trials was also associated with increased prescribing of the
study drug [27,29]. Against intuition, the higher the number
of clinical studies conducted in total [27], or for the sponsor
[27,29], the lower doctors’ sense of identification with a
new drug and the lower the likelihood of prescribing it.
CME and pharmacotherapy audit meetings (PTAMs)
(n = 3) [11,22,23]. Dybdahl et al. [22] found that CME
was significantly and positively associated with new drug
uptake in some clinical areas—however, the association
was weak and inconsistent across drug classes. Greving
et al. [11] found no relationship between CME and new
drug uptake and reported negative relationships between
doctors involved in PTAMs and new drug uptake.
Florentinus et al. [23] did not analyse the differences in
new drug uptake between GPs who attended PTAMs
voluntarilyc and those who opted out, but they did ana-
lyse the effects of PTAMs on early new drug prescribing
by GPs. GPs who attended low-quality PTAMs—without
structure or concrete outcomes—were more than twice
as likely to prescribe new drugs early post-marketing
than those who attended high-quality PTAMs—with fre-
quent concrete outcomes and outcome evaluations. The
authors argued that high-quality PTAMs may restrict the
number of new drugs GPs can prescribe, or may foster a
rather negative attitude towards prescribing new drugs,
but found no empirical evidence. Moreover, the authors
found that increases in the number of GPs—and pharma-
cists—attending PTAMs led to increases in new drug pre-
scribing by GPs. These findings underscore the social
network aspect of such forums, which facilitate interac-
tions among healthcare professionals. Doctors who attend
more or larger forums interact and influence one another’s
prescribing more than they would otherwise. The section
‘Contagion through social networks’ discusses the role of
social networks in new drug uptake in further detail.
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A possible measure of scientific orientation, the number
of professional journals doctors read is a variable quantifi-
able only through survey. Peer-reviewed journals are im-
portant sources of information on new drugs [8,43,46].
Sound research evidence is considered very influential in
reaching prescribing decisions [42,43].
Three studies assessed the impact of professional
journals on new drug uptake [7,11,15]. Two of these
used the same dataset and reported that the higher the
number of journals read, pharmaceutical company news-
letters and scientific and professional publications in-
cluded, the earlier doctors adopted new drugs [7,15].
However, Greving et al. [11] concluded that new drug
adoption among GPs was still determined more by pro-
motional than professional information—no significant
relation was observed between the use of scientific med-
ical journals and new drug uptaked.
Perceived scientific orientation (n = 3) [7,15,22]. Coleman
et al. [7] measured doctors’ perceived scientific orientation
—through (dis)agreement with the statement ‘it is more
important for a physician to keep himself informed of new
scientific developments than to devote more time to his
patients’—and found that profession-oriented doctors
used new drugs earlier than patient-oriented doctors, a
conclusion confirmed by Van den Bulte and Lilien’s [15]
reanalysis. In contrast, Dybdahl et al. [22] found no clear
association between self-rated GP clinical interest and new
drug uptake.
Specialist meetings and events (n = 3) [7,13,14]. Spe-
cialist meetings, congresses, conferences, and symposia
contribute to professional development—by providing a
highly valued source of information and acting as cata-
lyst for early awareness and positive evaluation, such
forums may accelerate the early adoption of new drugs.
In their classic study, Coleman et al. [7] found that
doctors who attended many out-of-town speciality meet-
ings—or who conscientiously attended conferences in
their own hospitals—were more likely to innovate than
others. Non-speciality meetings and county medical
society meetings had no influence over new drug up-
take. In a recent, carefully designed study, Liu and
Gupta [13] also reported that attending professional
events had a positive impact on new drug uptake. Mark
et al.’s [14] bivariate analysis found that doctors who
had attended a professional meeting within the past
five years were more likely to innovate. Their multi-
variate analysis, however, found that attending profes-
sional events did not influence new drug prescription
significantly.
Position (n = 1) [15]. Van den Bulte and Lilien [15]
found that hospital doctors in managerial or honorary
positions adopted new drugs later than others, due to
limited involvement in actual medical practice.Prescribing characteristics
Fifteen of the 35 eligible studies investigate at least one
prescribing characteristics [6,7,12-14,18,19,24,27-30,33,
34,36].
Prescribing volume in the therapeutic class of the new
drug (n = 11) [6,7,12-14,27-30,33,36]. Ten of the 11 stud-
ies found that the higher the prescribing volume in the
therapeutic class of a new drug, the higher the likelihood
of early adoption of that new drug [6,7,12-14,28-30,
33,36]. Although Iyengar et al. [12] found supporting
empirical evidence for only one of two drugs, the vari-
able is likely to remain significant when summing up the
prescribing volumes of the two drugs. Mark et al. [14]
used stated preference for new medication within the
drug class as variable and confirmed the relationship in
the bivariate model, but not in the multivariate model—
an insufficiently powerful result. Against mainstream
research, Glass [27] reported that doctors with higher
prescribing volumes in the therapeutic class of the study
drug were more reluctant to prescribe the study drug,
once on the market, possibly due to strong preferences
for other drugs.
Total number of patients/prescriptions (n = 9) [12,14,
19,24,27-30,34]. To address the unfulfilled medical needs
of some of their patients, doctors with high patient flows
seem particularly alert to new drugs. Six of the nine
studies reported that the higher the total prescribing vol-
ume, the higher the likelihood of early adoption of new
drugs [19,24,27,28,30,34]e. In contrast, the other three
studies showed no relationship between the number of
patients/prescriptions and new drug uptake [12,14,29].
However, Glass and Rosenthal [29] found that once
doctors had written at least one prescription for the
study drug, the total number of pre-study prescriptions
became a significant variable. Also, Mark et al.’s [14]
bivariate model found that the more schizophrenia pa-
tients doctors were treating, the earlier they adopted
atypical medication—the variable became an insignifi-
cant determinant of new drug uptake only in the multi-
variate analysis.
Prescribing volume of drugs by the same pharmaceut-
ical company (n = 4) [27-30]. Unambiguously, all four
studies found that the higher the prescribing volume of
drugs by the same pharmaceutical company, the higher
doctors’ likelihood of early adoption of other drugs by
that pharmaceutical company [27-30]. The authors ar-
gued that doctors are likely to prescribe new drugs if
already writing high numbers or large percentages of
prescriptions from the sponsoring company—either due
to increased detailing by that pharmaceutical company
or to doctors’ confidence and trust in that company or
in the company’s sales representatives [27-30]. The high
explanatory power of this variable is evidently related
to the marketing efforts of pharmaceutical companies
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Portfolio width (n = 1) [18]. Bourke and Roper [18]
defined portfolio width as the percentage of drugs pre-
scribed by individual GPs out of the portfolio of drugs
prescribed by all the GPs in that practice. Most probable,
this variable correlates highly with practice size—the
more patients doctors treat, the more likely they are to
require a larger portfolio of drugs from which to pre-
scribe. The authors found that the time to adoption was
decreasing substantially with increasing portfolio widths,
for all six study drugs. A 1 per cent increase in a GP’s
portfolio width decreased time to adoption between
three and 10.5 months, the variable having very high ex-
planatory power.
Marketing efforts targeted at doctors
Pharmaceutical companies typically direct their market-
ing efforts at doctors and—of late—patients. Several
studies reported that doctors had negative to neutral at-
titudes towards promotional efforts targeted at them and
tried to minimise the importance of sales representa-
tives, to avoid distorted, selective, and overly positive
information [47-49]. Nevertheless, detailing (personal
selling through sales representatives) is an inexpensive
and convenient source of information. Generally, GPs
indicated greater preference for commercial information
than SPs—time constraints and the broader range of
conditions they treated did not allow them to review sat-
isfactorily all relevant professional information [8,49,50].
The marketing efforts directed at doctors comprised
detailing, sampling (provision of drugs free of charge),
doctor meetings and events, and advertisements in med-
ical journals [48,51]. They aimed to boost profits by in-
corporating new drugs early in their lifecycles, by raising
awareness among top professionals, and by maintaining
the new drugs’ first-choice statuses within their respect-
ive therapeutic groups [52]. Pharmaceutical marketing
not only raises awareness—it evidently influences deci-
sion making too. Six of the 35 eligible studies investigate
some aspects of the marketing efforts targeted at doctors
[7,12-14,38,39]. The empirical evidence presented below
shows that pharmaceutical promotion affected prescrip-
tion behaviour positively, albeit to various degrees.
Detailing (n = 6) [7,12-14,38,39]. Historically, detailing
has been the primary promotional instrument of the
pharmaceutical industry—one third of total marketing
expenditure has been directed at detailing [51]. Four of
the six studies reported that doctor-targeted detailing
affected early adoption of new drugs significantly and
positively—doctors tended to respond to both current
and past detailing positively [12,13,38,39]. In contrast,
the other two studies found no empirical evidence for
the positive impact of detailing [7,14]. However, Burt[53] used the same dataset as Coleman et al. [7] and
found a significant association, possibly due to methodo-
logical differences. Studies reporting positive influences
used sales call data from pharmaceutical company re-
cords, whereas studies reporting no empirical evidence
used survey data—norm-conforming doctors with nega-
tive attitudes towards sales representatives may have re-
ported less contact than they actually had.
The marketing literature has documented well the im-
pact of pharmaceutical promotions on doctors’ choices,
including through extensive reviews [48,54]. Early stud-
ies used aggregate data [55-58], and almost all studies
found a strong positive effect of detailing on sales
[48,54]. Recent research used behavioural data [59-61]
and came to the broad consensus that detailing affects
the number of prescriptions for new drugs positively and
significantly. This effect was robust to a wide variety of
model specifications and datasets [48,54]. To provide a
more complete picture of sales and prescribing behaviours,
several recent models added numerous other marketing
variables and found that detailing had a positive and signifi-
cant effect on sales, even after controlling for other market-
ing mix instruments [48,54]. Most studies also found that—
relative to other marketing instruments—detailing had the
largest effectf.
Sampling (n = 2) [38,39]. Both studies found that the
volume of samples that had been left with doctors in the
past had a significant and positive impact on adoption
behaviour [38,39], even if the impact was very small
[39]. These findings were in line with the overarching
conclusion of the drug marketing literature [59,60].
Direct-to-consumer advertising (DTCA) (n = 1) [13]. If
allowed, DTCA in the mass media may influence early
adoption of new drugs through patient requests targeted
at doctors. In general, due to time constraints and the
desire to avoid conflict and increase patient role in deci-
sion making, doctors honour patient requests [49]. The
eligible study found that the volume of patient requests
for a new drug had a positive and significant impact on
doctors’ adoption decisions [13], and the extant market-
ing literature contributed to a more complete under-
standing of how DTCA impacted the demand for new
drugs. Two rigorous literature reviews concluded that
DTCA was associated with increased prescribing of ad-
vertised products, due to substantial impact on patients’
requests for specific drugs and doctors’ prescribing con-
fidence [54,62]. When detailing was controlled for, pro-
motions aimed directly at doctors turned out to affect
prescription choice much more than promotions aimed
at consumers [54,63-66]. DTCA had only a short-run
effect on choice, whilst the effect of detailing wore out
slowly, over the course of the year. There is a general con-
sensus in the literature that DTCA is effective in generat-
ing foot traffic into doctors’ offices and increasing the
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fecting doctors’ prescribing choices within the therapeutic
class [64,66,67]. Once patients get to see their doctors,
detailing and sampling have the most significant effect on
what drugs doctors choose [64-66]g.
Pharmaceutical companies may facilitate new drug
awareness in many other ways, all with a substantial pro-
motional component—for example, funding of clinical
trials, sponsoring of conferences and CME, and journal
advertisements. Kremer et al. [54] reported that the
elasticities of these other direct-to-doctor instruments
are significant, but modest in size. This review discusses
the impact of these other—partly scientific, partly pro-
motional—efforts in relation with variables measuring
doctors’ scientific orientation (see the section ‘Scientific
orientation’).
Contagion through social networks
When new drugs are launched, doctors’ behaviours are
affected by other doctors’ knowledge, attitudes, and be-
haviours, thus reducing safety and efficacy uncertainties.
Interpersonal communication between opinion-leading
doctors and peers seems critical to fast—and wide—ac-
ceptance of innovative drugs [8,50,68]. Personal contacts
may provide real stimuli, since key opinion leaders present
reliable, easy-to-digest assessments of new drugs. While
other sources of information provide the nurturing ground-
work of necessary knowledge, behavioural change requires
the legitimising power of personal advice from informed
and respected colleagues [69].
The main findings of the six eligible studies [7,12,
13,15,36,38] are summarised below, in chronological
order—five of them found empirical evidence for con-
tagion, even after controlling for a wide variety of
factors.
In their path-breaking and highly cited Medical
Innovation: A Diffusion Study, Coleman et al. [7] ar-
gued that the network of informal relations among
doctors was highly effective in transferring information
and influencing the diffusion of pharmaceutical inno-
vationsh. Doctors’ adoption decisions were affected by
interactions with other doctors—socially integrated
doctors introduced new drugs quicker than their more
isolated colleagues. The finding was found valid for
all three social structures of the medical community
studied—advisor, discussion, and friendship networks.
However, doctors’ professional interactions had a lar-
ger effect on adoption time than social interactions.
Moreover, the channels of influence among doctors
operated most powerfully during the first few months
after the release of a new drug.
Van den Bulte and Lilien [15] found that contagion ef-
fects disappeared when journal advertising was con-
trolled for—first entrants’ marketing efforts, not socialcontagion, were the dominant driver in increasing doc-
tors’ adoption hazard with time. The authors explicitly
underscored the importance of controlling for potential
confounds, such as marketing efforts, when studying the
role of social contagion in new drug diffusion. In a sub-
sequent working paper, deemed ineligible because it did
not meet the first eligibility criteria, they used new event
history models for a two-stage adoption process—aware-
ness followed by evaluation and adoption [70]. When
marketing efforts were allowed to affect awareness and
social contagion was allowed to affect evaluation, both
effects became statistically significant. In the presence of
strong mass media effects, the patterns of social conta-
gion were weak—contagion had a significant effect in
the second stage.
In their carefully designed study, Manchanda et al.
[38] found that doctors’ decisions to adopt were influ-
enced positively by contagion—that is, doctors’ probabil-
ities to adopt increased significantly with increases in
fellow doctor adoption. The authors determined the so-
cial networks of doctors on basis of geographic proxim-
ity, defined as the area within a 20-mile radius around a
doctor’s office. The observed positive and significant
contagion effect persisted even after controlling for time
trends and marketing efforts. The authors ruled out
many alternative explanations, including uniqueness of
the social networks under analysis or unobserved com-
mon variables that affect all the network members simi-
larly—for example, sales representatives or institutional
factors such as working for the same hospital, using the
same formularies, and attending the same meetings and
events sponsored by pharmaceutical companies.
Interestingly, Manchanda et al. [38] had also calculated
the proportion of adoption probability arising from mar-
keting activity relative to that arising from contagion
and had found that marketing played a larger role in
adoption earlier on. However, consistent with Iyengar
et al. [12] and Narayanan et al. [65], contagion domi-
nated from month 4 onwards, asymptoting to around 90
per cent of the effect by month 17.
In a partly similar setting, Liu and Gupta [13] also found
that the estimated effect of contagion among doctors in
geographic proximity was positive and significant.
In a carefully and insightfully designed study, Iyengar
et al. [12] reported that doctors with high indegrees
adopted early, and found evidence of social contagion
primacy over social network ties even after controlling
for targeted marketing efforts and time shocks. Adoption
was affected by peers’ prescribing volume within the
drug class, rather than by peers’ adoption per se. Due to
credibility granted by experience with a newly intro-
duced drug, doctors who prescribed a new drug more
often were more reliable sources of information—not
only did they follow their own recommendations, but
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Lin et al. [36] also found evidence for contagion.
Overall, peers’ and opinion leaders’ adoption ratios were
positively associated with the likelihood of early adop-
tion. Of the three age-based groups (younger colleagues,
compeers, and older colleagues), compeers’ and older
colleagues’ adoption ratios were correlated with doctors’
likelihood of early adoption positively. Of the three
tenure-based groups (junior colleagues, compeers, and
senior colleagues), compeers’ and senior colleagues’ adop-
tion ratios were associated with doctors’ likelihood of early
adoption positively and significantly. The authors con-
cluded that professional authority and informal interaction
were equally important in the adoption process. While
older doctors with longer tenures were granted profes-
sional authorities implicitly, on grounds of clinical ex-
perience, compeers in age and tenure exerted similar
influences through more direct and frequent interactions.
The authors argued that—besides senior colleagues, as al-
most exclusively advocated in the literature—peers should
also be taken into account.
Practice characteristics
Eighteen of the 35 eligible studies investigate at least one
practice-related characteristics of prescribers [1,5-7,11,
12,14,16-18,20,21,24,33,35-37,40].
Location (urban or rural) (n = 7) [1,5,6,11,16-18]. Rural
practice locations may result in late new drug adoption—
in contrast with their urban colleagues, rural doctors have
fewer opportunities for professional interactions with
peers, an important factor in the decision to initiate new
treatments. The lower new drug utilisation rates in rural
practices might also be explained by the lower number of
visits by pharmaceutical sales representatives [5], due to
geographic inaccessibility, or by the personal characteris-
tics of doctors who elect to practice in rural communities.
At least partly, three of the seven eligible studies
tended to favour the idea that urban practices adopt
earlier and rural practices adopt later [1,6,18]. Tamblyn
et al. [1] found that rural doctors were less likely to pre-
scribe new drugs than their urban colleagues. Albeit only
for two of six study drugs, Bourke and Roper [18] also
reported an increase in time to adoption for practices in
receipt of rural practice allowances. Finally, Groves et al.
[6] concluded that the upper quartile of high-relative
doctors may be best classified as doctors with urban
practices. However, three other eligible studies found no
evidence of early adoption of new drugs in urban areas
[5,16,17], suggesting a reassuring efficiency of informa-
tion dissemination. At the other extreme, two eligible
studies found that rural practices adopted earlier [6,11].
Greving et al. [11] reported that GPs who worked in
rural areas were more likely to prescribe new medicationthan others, whereas Groves et al. [6] found that doctors
classified as high-total new drug prescribers were more
likely to operate in rural areas than elsewhere, possibly
due to high patient—including elderly patient—loads.
Type (solo or group/partnership) (n = 7) [7,11,12,20,
33,35,40]. In group/partnership practices, continuous
professional stimulation and other social factors may
accelerate the early adoption of new drugs. Joint respon-
sibility for patients may promote the circulation of med-
ical notes and allow for cross-fertilisation of therapeutic
information [68], while daily personal contact with col-
leagues may provide an efficient channel for information
transfer and evaluation. (For a discussion on the role of
social networks in early adoption of new drugs, see the
section ‘Contagion through social networks’.) However, the
impact of group/partnership practices on new drug uptake
is ambiguous in the literature [7,11,12,20,33,35,40].
On the one hand, Coleman et al. [7] reported that doc-
tors who practised in groups/partnerships introduced
new drugs on average 2.3 months earlier than doctors
who practised solo—two other studies supported these
findings [33,40]. On the other, four of the seven eligible
studies arrived at different conclusions. Iyengar et al.
[12] and Kozyrskyj et al. [35] found no significant rela-
tionship between type of practice and early adoption of
new drugs, whereas Dybdahl et al. [20] argued that the
differences between solo and group/partnership practi-
tioners disappeared after adjustment for practice size. Fi-
nally, Greving et al. [11] found that higher levels of new
drug prescribing were associated with solo practices.
Size (n = 6) [1,5,16,21,36,40]. Practice size may be
measured in number of doctors, number of patients,
prescribing volume, or number of services delivered.
Intuitively, the larger the practice, the higher the prob-
ability of patients with conditions targeted by new
drugs. However, only one of the six eligible studies
favoured clearly the idea that larger practices adopt
new drugs earlier than smaller practices. Steffensen
et al. [40] found that the higher the number of patients,
the higher the likelihood of early adoption. Tamblyn
et al. [1] also found a modest but significant associ-
ation between the two variables, but higher numbers of
services delivered had different relationships for GPs
and SPs, increasing the rate of new drug use for GPs,
while reducing that for SPs. The other four studies
found no empirical evidence for association between
large practice size and early adoption of new drugs—
whether size was measured by total prescribing volume
[5,21], by volume of prescribing within the therapeutic
class of the new drug [21], by number of doctors
[16,36], or by number of patients [16,21].
Ownership (public or private), management (reformed
or non-reformed), and orientation (for profit or not for
profit) (n = 4) [5,24,36,37]. Ohlsson et al. [5] and Lin
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to adopt new drugs earlier than public practices. In a
similar setting, García et al. [24] reported that doctors in
reformed institutions—under the management of dis-
tinct autonomous communities—adopted earlier than
doctors in non-reformed institutions—operated by the
National Institute of Health Management. This finding
was very country specific, but supported the idea that
autonomy may stimulate new drug diffusion. In contrast,
Liu et al. [37] found that doctors in not-for-profit insti-
tutions were more likely to prescribe new drugs than
doctors in for-profit institutions. The authors argued
that for-profit hospitals delayed the introduction of new
drugs in formularies—even if that hindered quality im-
provement—due to very strong incentives to reduce
costs. However, this argument is at loggerheads with pa-
tients’ freedom to choose other hospitals, as well as in
need of further evidence—the respective coefficients be-
come insignificant, when standard errors are adjusted.
Region (n = 4) [12,14,24,37]. Four studies examined
regional impact on new drug diffusion through city or
region dummies. Three of them found no differences
across geographic locations [12,14,24], whereas Liu et al.
[37] found that doctors in Taipei and central Taiwan
were more likely to prescribe new drugs than doctors
elsewhere in Taiwan. The authors argued that the speed of
technological diffusion might depend on market size—
most probably, pharmaceutical companies concentrated
their marketing efforts on larger cities, with higher
population densities and higher family incomes. However,
considerable regional differences in Taiwan make general-
isation difficult—regions may play an important role in
more centralised countries and no role in more decentra-
lised countries.
Accreditation level (n = 2) [12,37]. Iyengar et al. [12]
used a dummy variable to indicate whether doctors
worked in—or were affiliated with—a university or
teaching hospital, and found no significant association
between level of institutional accreditation and new
drug uptake. In contrast, Liu et al. [37] reported
that accreditation levels—positively associated with
practice size—had significant positive effects on the
probability of prescribing new drugs. Consequently,
academic medical centres had higher probabilities of
prescribing new drugs than metropolitan and commu-
nity hospitals. The authors argued that the higher the
accreditation level, the higher the institution valued
quality improvement—and the more inclined the insti-
tution was to prescribe new drugs. At the same time,
higher levels of institutional accreditation—and, thus,
higher market sizes—implied more significant market-
ing efforts from pharmaceutical companies.
Diagnostic and therapeutic activities (n = 2) [16,40].
The two studies found that high volumes of diagnosticand therapeutic activities were associated positively with
early adoption of new drugs [16,40].
Employee composition (n = 2) [5,18]. Ohlsson et al. [5]
found that practices employing SPs as well as GPs were
more likely to adopt new drugs early than practices
employing GPs only—this finding supports the two-step
model (see the section ‘Scientific orientation’). For two of
six study drugs, Bourke and Roper [18] found small but
significant lower adoption times for practices employing
the assistance of a nurse or secretary—for the other four,
no relationships were observed.
Other (n = 2) [1,37]. Tamblyn et al. [1] found that
higher referral rates were associated with significant
reductions in SPs’ new drug prescribing rates. Most
probably, SPs with higher referral rates treated patients
with more comorbidities that required more careful and
cautious prescribing. Liu et al. [37] reported that the
higher the healthcare market concentration—that is, the
higher the market share of certain practices in a given
region—the higher the probability of prescribing new
drugs. In contrast, the lower the healthcare market con-
centration—that is, the more competitive the market—the
lower the probability of prescribing new drugs. According
to Liu et al. [37], thus, high competition among healthcare
providers—often advocated by policy makers—hindered
new drug diffusion.
Drug characteristics
The majority of drug characteristics—improvement over
existing therapies and the safety and efficacy of new
drugs, for example—may require randomised controlled
trials over long time periods and may not be measured
easily. The five drug characteristics measurable quantita-
tively are the marketing budget of the pharmaceutical
company assigned for the new drug, overall acceptance,
therapeutic novelty, competition, and cost. Thirteen of
the 35 eligible studies investigate at least one of the five
quantitatively measurable drug charachteristics [1,13,15,
18,20,25,27-30,33,37,38].
Marketing budget of the pharmaceutical company
assigned for the new drug (n = 7) [1,13,15,28-30,38].
The marketing budget of the pharmaceutical company
assigned for a new drug affected early adoption in five
of the seven studies, exerting significant and consist-
ently signed influence—doctors were more likely to
prescribe more heavily marketed drugs [13,15,28-30]i.
This influence was more pronounced for first entrants
than for subsequent ones [15].
The other two studies arrived at different conclusions.
Manchanda et al. [38] used monthly DTCA expenditure
as proxy for aggregate marketing expenditure, and found
no association with doctors’ adoption behaviour—not
entirely surprising, since DTCA was zero in the first ten
months after launch. Tamblyn et al. [1] also found no
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intensity—measured by detailing minutes and advertis-
ing pages—and early adoption of new drugs.
Overall acceptance (n = 6) [13,18,27,29,30,38]. Six stud-
ies assessed the influence of time on new drug uptake by
encompassing many potential influencers—for example,
overall acceptance, growth in patient base, and the aggre-
gate diffusion pattern in a geographic area. Manchanda
et al. [38] and Liu and Gupta [13] controlled systematically
for factors that might influence doctors’ adoption behaviour
over time by adding time trend terms to their models—
number of months lapsed since launch (for linear effects)
and the same variable squared (for non-linear effects). The
authors found unequivocally that temporal effects influ-
enced new drug uptake significantly—however, the sign var-
ied with the convexity of the temporal diffusion trend.
Similarly, Glass [27] and Glass and Rosenthal [29] con-
trolled for overall acceptance 12 months after launch by
adding a market share variable. In line with intuition, the
authors found that doctors were more likely to prescribe
new drugs that were highly prescribed by other doctors.
Bourke and Roper [18] also included an overall acceptance
variable—the time-variant percentage of GPs who had
adopted the study drug. The authors found a significant ef-
fect—for five of six study drugs, time to adoption increased
with increases in the number of previous adopters. They
explained the counterintuitive sign of the effect through
market saturation—the longer the time, the fewer the GPs
who had not already adopted. As an exception, Glass and
Dalton [30] reported that market share 12 months after
launch was not a significant variable in explaining the vol-
ume of new drug prescriptions.
Therapeutic novelty (n = 3) [25,27,33]. Garjón et al.
[17] found that tiotropium—the only drug rated as
therapeutic innovation—was adopted the most widely
and quickest. Huskamp et al. [33] also reported that the
four original antipsychotic formulations were quicker
and more widespread adopted than reformulations. In
contrast, Glass [27] showed that the prescribing level of
the study drug six months after launch was not related
to its therapeutic novelty. However, neither Huskamp
et al. [33] nor Garjón et al. [25] could affirm that thera-
peutic novelty was the main reason for rapid new drug
diffusion.
Competition (n = 1) [37]. Liu et al. [37] reported that
the probability of prescribing new drugs was negatively
associated with the level of competition in the pharma-
ceutical market—when new drugs entered therapeutic
subgroups, the prescribing probability decreased by 0.2
percentage points. They argued that the profit margins
of pharmaceutical companies increase with increases in
the number of products they launch, given the unregu-
lated character of the wholesale market—unlike the reim-
bursement price, the acquisition price is not determinedby the regulator. Hence, profit margins will be larger for
older drugs than for new drugs, and the probability that
doctors will prescribe new drugs will be smaller.
Cost (n = 1) [20]. Dybdahl et al. [20] found that adop-
tion time adjusted for number of listed patients was only
weakly associated with the cost of new drug prescribing.
The survey-based literature suggested that cost is less
important than both safety and perceived efficacy [47],
in general, and does not represent a significant barrier in
the early adoption of new drugs [71]. Doctors try to bal-
ance efficacy and cost, but are not reluctant to prescribe
higher cost, more effective drugs [44,72]. Jacoby et al.
[43] found that the most frequent early adopters of new
drugs were the least cost conscious.
Patient characteristics
Patient characteristics such as age, gender, socioeco-
nomic status, and the presence of comorbidities seem to
influence new drug uptake. On the one hand, the empir-
ical evidence is vast—on the other, characteristics of
early receivers vary from drug to drug, with therapeutic
goals and the target audience of the drug. An exhaustive
review of the relevant literature is therefore impossible.
Nine of the 35 eligible studies investigate at least one pa-
tient characteristics [1,5,11,13,14,16,32,35,37], their find-
ings are discussed briefly in the following paragraphs.
Age (n = 9) [1,5,11,13,14,16,32,35,37]. Doctors’ likeli-
hood of continuing to prescribe particular medications
seemed to be influenced by patients’ age. Since elderly
patients were more likely to experience side effects, doc-
tors were less likely to prescribe new drugs to older pa-
tients [1,16] and more likely to prescribe new drugs to
younger patients [5,11,14]. Drugs generally designed for
the elderly—to treat Alzheimer’s disease or arthritis, for
example—were of course exceptions [32]. At the same
time, three of the nine eligible studies found that pa-
tients’ age was not an important factor in new drug up-
take [13,35,37].
Gender (n = 6) [5,11,14,32,35,37]. Five of the six studies
found that patient gender exerted small influence—if
any—on doctors’ prescribing [11,14,32,35,37]—new drug
characteristics and therapeutic goals were usually more
important influencers. However, exceptions do occur—
Ohlsson et al. [5] reported that more new drugs were
prescribed to male than female patients.
Health (n = 4) [11,14,35,37]. Patients’ health statuses—
self-reported health, poor response to existing therapies,
previous use of certain medications, and presence of co-
morbidities—evidently played an influential role in new
drug uptake [11,14,37]. The variables reflecting signifi-
cant associations included: patient referrals to cardiolo-
gists or internists, regardless of number of comorbidities
[11]; higher comorbidity indexes; higher severities of dia-
betes, as measured by number of prescriptions per visit
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symptoms in Mark et al.’s [14] multivariate model. How-
ever, chronic arthritic conditions made an exception, not
playing an influential role in new drug prescribing for
the majority of study drugs [35]. Generally, doctors
seemed to consider individual contexts seriously, and pa-
tient convenience seemed to influence new drug uptake
and promote earlier adoption among patients at desper-
ate stages.
Socioeconomic characteristics (income, education, and
health insurance) (n = 4) [5,13,14,35]. By definition, socio-
economic statuses reflect patients’ economic and social
positions relative to others, based on income, occupation,
and education [73]. Three of the four eligible studies sug-
gested that patients’ socioeconomic statuses influenced
doctors’ prescribing behaviour irrespective of medical con-
siderations [5,13,35]. High-income patients received new
drugs earlier than others, not least because of their ability
to pay for out-of-pocket treatments [5,13,35]. Privately in-
sured patients or patients with a higher insurance index
also seemed more likely to receive new drugs earlier than
others [13]. However, Mark et al. [14] found no empirical
evidence for positive impact of higher level of formal edu-
cation and better insurance status on new drug uptake.
Marital status (n = 2) [5,14]. Marital status may influ-
ence new drug uptake, but to lesser extent than socio-
economic status. Prescriptions for the treatment of high
blood cholesterol were more probable among married or
cohabiting patients [5], whereas prescriptions of atypical
antipsychotics were equally likely among single patients
and married or cohabiting ones [14].
Race/ethnicity (n = 2) [13,14]. Association between
race/ethnicity and socioeconomic status suggests asso-
ciation between race/ethnicity and new drug uptake.
For example, non-African Americans were more likely
to be treated with new medications than African
Americans and Hispanics [13,14].
Discussion
For patients to receive the best possible care, doctors
have to consider the risks and benefits of new drugs in
conjunction with patient characteristics. Prescribing is a
complex exercise, and early adoption of new drugs is the
outcome of interactions among a wide variety of factors.
The determinants of the decision to prescribe are inter-
connected in many—often conflicting—ways. This sys-
tematic review of the literature revealed a number of
micro- and meso-level variables that produced consist-
ent prediction of early adoption.
At prescriber level, the most significant influencers in-
cluded interest in particular clinical or therapeutic areas,
clinical trial participation, prescribing habits, targeted
marketing efforts of pharmaceutical companies, and peer
pressure through interpersonal communication.Interest in particular clinical or therapeutic areas exerted
influence on new drug uptake in the majority of cases.
Early adoption of new drugs was more likely among SPs
than GPs, whether drugs were special-purpose or for wide
therapeutic spectra—new drugs diffused into general prac-
tice slower, because GPs preferred to follow the prescrib-
ing norms set by SPs. Partly related to clinical interest,
clinical trial participation was also a powerful predictor of
early adoption.
Prescribing habits were one of the most powerful pre-
dictors of new drug uptake. Not surprisingly, the greater
the number of prescriptions written for all types of drugs
or only within the therapeutic class of the new drug—
and the wider the prescribing portfolio—the greater the
chances of writing prescriptions for the new drug. High
prescribing volumes in the therapeutic class of a new
drug may lead to early adoption of that new drug for
various reasons [13,33]: (1) doctors are subject to en-
hanced adoption risk, because of large numbers of pre-
scriptions; (2) doctors are likely to encounter patients
who match the recommended patient profile of the new
drug, because of diversified patient pools; (3) doctors
may find it worthwhile, because the new drug may bene-
fit other patients too; and (4) doctors are likely to be tar-
geted by the marketing efforts of drug manufacturers.
The prescribing volume of drugs by the pharmaceutical
company introducing the new drug was also a powerful
predictor of new drug uptake.
Pharmaceutical companies provide knowledge, in-
crease product awareness, and direct further information
acquisition. Accordingly, the size and efficiency of the
marketing efforts targeted at doctors were very powerful
predictors of new drug uptake. The reviewed studies
showed almost unambiguously that pharmaceutical mar-
keting had a significant and positive influence on pre-
scribing. Among marketing efforts, detailing had the
largest impact on new drug uptake, being robust to a
wide variety of model specifications and datasets. Sam-
pling, patient requests resulting from DTCA, and other
direct-to-doctor marketing also influenced new drug up-
take positively—however, their impact was rather mod-
est. Promotional information continuing to influence
early adoption—Manchanda and Honka [48] argued that
pharmaceutical marketing involving billions of dollars is
clearly here to stay.
Interpersonal communication—professional and so-
cial—also appeared to be a very important influencing
factor, with information relayed through direct, per-
sonal contacts proving particularly powerful in new
drug uptake. With the exception of Van den Bulte and
Lilien [15], the other relevant eligible studies found
empirical evidence of social contagion in new drug
adoption effectuating in the form of consumption ex-
ternality [7,12,13,36,38]. Interpersonal communication
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of influence over new drug uptake—and has important
implications for both pharmaceutical companies and
healthcare strategists. Pharmaceutical companies should
continue to devote significant proportions of their market-
ing budgets to sales representatives, and should target cus-
tomised and scientifically valuable information at key local
opinion leaders. The practice of targeting heavy pre-
scribers is a good strategy, common in the pharmaceutical
industry—these prescribers not only have a high customer
lifetime value, but also a high network value, through
exerting more social contagion. At the same time, health-
care strategists should be very careful with projects that
rely on electronic databases—efforts to utilise objective in-
formation to improve prescribing had ambiguous out-
comes [47]. Preferably, healthcare strategists should rely
on SPs to systematically disseminate new drug informa-
tion and prescribing guidelines.
In addition, overseas qualifications and graduation
from the youngest medical schools were also associated
with higher rates of new drug uptake. More likely than
not, unmeasured aspects of the training environment in-
fluenced new drug use—basic pharmacological training,
policies related to drug detailing, relative financial con-
tributions by pharmaceutical industries to training and
research, or the educationally influential practices of at-
tending doctors during formative training years [1].
There is a growing emphasis on evidence-based medi-
cine suggesting that professional information counter-
balances commercial information [7,15]. In line with this
shift, perceived scientific orientation, the number of pro-
fessional journals read and attendance of specialist meet-
ings and events also seemed to favour early adoption,
with the exception of high-quality or low frequency
PTAMs, which seemed to hinder it. However, drawing
firm conclusions is difficult with such narrow research
bases.
At practice level, only a few variables predicted early
adoption consistently, in a small number of eligible stud-
ies—gaining insight into their roles would benefit from
further research. The volume of diagnostic and thera-
peutic activities was consistently associated with new
drug uptake. High volumes of diagnostic and therapeutic
activities may be indicative of patient health severity,
and of the need for early adoption of new drugs. Prac-
tices employing SPs as well as GPs—or employing more
non-medical professionals—had higher rates of new drug
uptake. Private healthcare institutions also seemed more
likely to adopt new drugs earlier than public healthcare
institutions.
At drug level, most characteristics may only be
measured through randomised controlled trials over
long periods of time. However, the marketing budgets
pharmaceutical companies allocate for new drugs are aquantitatively measurable consistent predictor of new
drug uptake. In line with expectations, the higher the
marketing budgets, the faster the adoptions. Evidently,
aggregate marketing expenditure correlates highly with
the quality and quantity of marketing efforts targeted
at specific doctors. Increasing the marketing budget of
pharmaceutical companies may pay off, if marketing
efforts are targeted efficiently at doctors—the marginal
cost equals the marginal revenue of marketing.
Although research evidence was scant, overall accept-
ance and therapeutic novelty seemed to favour new drug
uptake. One might reasonably assume that the factors
affecting the uptake of highly innovative drugs might dif-
fer from the factors affecting the adoption of me-too
drugs. In general, factors being consistently associated
with new drug uptake were powerful predictors for both
types of the drugs. Glass and Rosenthal [28] assessed the
highly innovative drugs and me-too drugs in two distinct
logistic regression models—their study was the only eli-
gible one performing separate analysis in the function of
innovation. The authors found that several variables
were common to the adoption models for both types of
drugs, including total prescribing volume, clinical trial
participation, marketing budget of the pharmaceutical
company assigned for the new drug, being a specialist
in the respective specialty of the study drug and having
office-based practices. The most striking difference be-
tween the two models was the role played by prescrib-
ing volume of the drugs by the same pharmaceutical
company. This variable was not present in the model
built for me-too drugs, yet it was the most important
variable in the model assessing highly innovative drugs.
The authors argued that this difference might indicate
a degree of confidence and trust in that company, or in
that company’s sales representatives, by the physician
prescribing a therapeutically novel new drug from that
company.
When highly innovative drugs are prescribed reducing
safety and efficacy uncertainties is of crucial importance.
Trust in the pharmaceutical company in providing a safe
and efficacious novel drug seems to associate positively
with new drug uptake [28]. Formal and informal contact
with colleagues is another way to reduce uncertainty—
empirical evidence suggests that these contacts are more
important in higher risk drug adoption than in me-too
drug uptake [50].
At patient level, consistent predictors of new drug
uptake included young age and high socioeconomic
status—high income, high level of formal education,
and belonging to the majority race/ethnicity of the
country. Furthermore, poor health status—either self-
reported or due to comorbidity or unsatisfactory re-
sponse to existing therapies—also promoted new drug
uptake.
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number of other variables was not possible, due to in-
consistent results.
At prescriber level, age and gender were debated
characteristics—in the majority of cases, no associations
were found. Where associations were found, young age
favoured early adoption, in line with intuition, and
male doctors prescribed new drugs earlier than female
doctors, most probably due to higher confidence with
regard to the initiation of new medical treatments to
achieve desired health outcomes [1,74]. Professional age
may correlate highly with age, but its impact on new
drug uptake was even less obvious—half of the relevant
studies reported positive associations, whereas the other
half reported negative associations. At the same time,
neither board certification nor hospital affiliation associ-
ated consistently with new drug uptake. With regard to
the latter both formulary restrictions and the heightened
professional orientation of hospital-affiliated doctors
played a role in the adoption process, with formulary re-
strictions slightly more so, at least in Northern America.
Evidence on doctors’ positions, nationalities, current
workplaces and the role CME plays in new drug diffusion
was scant, and more research is needed to draw reliable
conclusions. For example, with regard to nationalities,
any future studies should control for regulatory environ-
ments—including pressure on doctors to prescribe generics
cheaper than branded medicines—and country-level drug
marketing expenditures.
At practice level, several variables yielded inconsistent
results in quantifying the likelihood of new drug uptake.
Group/partnership practices associated with new drug
uptake in some studies, but not in all. In case of group/
partnership practices, adjusting for practice size is essen-
tial in determining whether early adoption of new drugs
stems from high number of patients or from continuous
professional stimulation. Previous empirical research had
rather suggested the former contention—group/partner-
ship practices adopted new drugs early, if they adopted
early at all, because they were (much more) likely to
meet patients in need of new drugs [20]. The higher the
number of patients a practice had, the higher the prob-
ability to consult patients who may have been candidates
for new drugs—a conclusion other authors [7,33,40] may
have drawn too, had they adjusted for practice size.
Practice location (rural or urban and central or periph-
eral) also did not predict consistently new drug uptake.
Some studies indicated effective methods of information
dissemination across geographical boundaries [5,6] (for
high-total new drug prescribers), [11,12,14,16,17,24], while
others not [1,6] (for high-relative prescribers), [18,37].
Modern communication technology, if used appropriately,
most probably enables rural doctors to be as up-to-date as
urban doctors—with abundant possibilities for CME andexchanges with colleagues, and with full access to infor-
mation from pharmaceutical companies.
Practice size—measured by number of patients or pre-
scribing volume—also did not associate consistently with
new drug utilisation. This inconsistency is not only
counterintuitive, but also at odds with the prescribing
characteristics discussed earlier. Presumably, the innova-
tive and conservative behaviours of individual doctors
cancelled one another out, when summed up at practice
level.
The impact of institutional accreditation on new drug
diffusion was also controversial in the reviewed literature,
one study finding positive association between level of in-
stitutional accreditation and new drug uptake, while an-
other finding no empirical evidence for the association.
At drug level, the cost of new drug prescribing was
only weakly associated with adoption time. Although
competition in the pharmaceutical market was nega-
tively associated with the probability of prescribing new
drugs in one study, more research is needed to draw re-
liable conclusions.
At patient level, characteristics of early receivers varied
from drug to drug, mostly with the therapeutic goal and
target audience of the drug. Accordingly, neither pa-
tients’ gender nor their marital status produced consist-
ent prediction.
This systematic review of the literature revealed a
number of micro- and meso-level factors that produced
either consistent or inconsistent prediction of early
adoption. Macro-level factors, providing the framework
for new drug diffusion, were so far not considered in this
review. Many healthcare institutions and professional or-
ganizations, however, play a critical role in the diffusion
process—their role is discussed briefly in the following
paragraphs.
Drug approval agencies regulate and supervise pharma-
ceutical products, without their permission no drugs can
be launched on the market. For example, in the EU a
medicine can only be marketed if it has been approved ei-
ther by the European Commission on the basis of the
European Medicines Association’s (EMA) scientific opin-
ion or by national competent authorities.
Once a regulatory agency has approved a new product,
a pharmaceutical company will typically submit it for
evaluation by a payer of some sort. Payers may be pri-
vate insurance plans, government agencies such as the
National Institute for Health and Care Excellence
(NICE) in the UK, or health care organizations such as
hospitals. Several public players apply cost-effectiveness
analysis to guide reimbursement decisions [75]. Public
payers have also started to negotiate risk-sharing agree-
ments with pharmaceutical companies in an effort to
mitigate the potential for an unexpectedly large budget
impact due to incorrect assumptions and projections
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supply-side controls aimed at limiting the cost of reim-
bursed medicines to the authorities. Additional measures
include price controls and limits on availability through
the use of positive and negative lists.
Once the decision on the rate of reimbursement is
made, the demand for new drugs still might be influenced
by a number of ways, such as education, engineering,
economic evaluation and enforcement [76]. Educational
activities include, among others, development and distri-
bution of prescribing guidance in which Drug and Thera-
peutic Committees (DTCs) play a crucial role. The DTCs
may be regarded as a tool for promoting more efficient
and rational use of medicines. Their drug recommenda-
tions are based on efficacy, safety, suitability and cost-
effectiveness [77]. The recommendations of essential
medicines, as a key component of rational use of medicines,
should be enhanced by several complementary strategies,
such as the ones defined in the Stockholm model [78].
With regard to demand-side measures, engineering ac-
tivities include organizational or managerial interven-
tions such as prescribing targets, whereas economic
interventions include penalties on devolved budgets, fi-
nancial incentives linked to prescribing targets, as well
as differential patient co-payments [76]. Enforcement in-
cludes regulations by law such as mandatory generic
substitution as well as prescribing restrictions [76]j.
This systematic literature review has several possible
limitations. First, it was undertaken by a single reviewer,
heightening the potential for errors in the coverage and
synthesis of the literature. Second, the chosen search
strategies may have failed to identify prescription-based
studies where new drug uptake was considered, but not
as key focus. Third, prescription-based studies have advan-
tages as well as disadvantages. They assess relationships
based on very large data sets—however, data collected by
health insurance funds are set up for insurance-related
purposes. Consequently, the structure and content of the
underlying data may not allow for answering certain re-
search questions. Fourth, registry-based studies capture
complex prescribing realities, but—without survey ques-
tionnaires and in-depth interviews—fail to encapsulate
them comprehensively. Survey-based variables that com-
plemented the registry-based variables were covered in
this systematic literature review, but their role was periph-
eral, given possible self-reporting bias—missing independ-
ent validation, the quality of their evidence may have been
suboptimal. Fifth, the studies reviewed here covered a
range of drugs, prescribers, geographic regions, and na-
tions—variance in results may have simply stemmed from
differences in drugs, prescribers, or locations. In some
cases, for example, the lack of concordance among study
findings was evidently a straightforward consequence of the
different drug characteristics and regulatory environments.Sixth, almost half of the eligible studies were US-based.
The regulatory environment, the pharmaceutical compan-
ies’ determination, and doctors’ general attitude towards
innovation evidently influence new drug diffusion. As yet,
unfortunately, the literature offers no comparison of the
influences of country-specific characteristics on new drug
diffusion.
Most probably, doctors who coordinate patient care
need to communicate regularly and effectively with
many other doctors who share responsibility for patient
care [79], allowing for the exertion of influence on new
drug uptake. In future, the recent availability of adminis-
trative data of health insurance funds [79-81] might
open new ways of identifying characteristics of early
prescribers, by allowing researchers to construct and
combine patient-sharing network data with doctors’
socio-demographic and professional characteristics on
a large scale.
Conclusions
This systematic literature review has provided insights
into the factors that affect new drug uptake—primarily,
doctors’ scientific orientation, prescribing habits, ex-
posure to pharmaceutical marketing, and interpersonal
communication. In relation to patient portfolios, doctors
with younger patients, patients with higher socioeco-
nomic statuses, and/or patients with poorer health sta-
tuses were more inclined to prescribe new drugs early.
Some socio-demographic characteristics and practice-
related factors also played an important role in the diffu-
sion process. With so many different variables likely to
influence new drug uptake, it is conceivable that each
variable has only a moderate impact, which may explain
the inconsistency of findings across studies.
Predicting doctors’ prescribing behaviour is an equally
complex and multifactoral exercise. It continues to
challenge researchers to gain clearer understanding of
influencing factors and their interactions, to benefit
all parties—whether patients, doctors, policymakers, or
pharmaceutical companies. However, models with high
numbers of variables and high explanatory power would
be needed to help healthcare policy strategists to perfect
interventions and pharmaceutical companies to optimise
marketing budgets.
The fierce competition in the healthcare market is
likely to stay—in search of profit, pharmaceutical com-
panies are keen to add new products to their portfolios
[3]. In contrast to Liu et al. [37], intuition suggests that
the more competitive the markets, the more efforts
pharmaceutical companies make to have their products
prescribed by doctors. As a result, more new drugs
would be prescribed in more competitive environments
than in less competitive environments, particularly if the
new drugs are innovative, cost-efficient and address
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early entry in combination with substantial market share
would render late entry irrelevant—anecdotal evidence
has it that doctors’ brains, already saturated by existing
brands, can be penetrated neither by late entrants’ re-
search and development activities nor by their marketing
efforts. Thus, pharmaceutical companies may be best
placed to develop both innovative drugs and models
forecasting early adoption.
Endnotes
aThere are two studies [6,35] in which both age and
professional age are used. These studies, however, do
not take interaction between age and professional age
into account.
bHowever, Florentinus et al. [82] found that GPs were
responsible for 20–30 per cent of first prescriptions.
cIn the Netherlands, PTAMs bring together—on a
regular and voluntary basis—pharmacists and GPs who
work in the same catchment area. Their aim is to im-
prove prescribing quality by deciding first-choice treat-
ments [23].
dTime constraints and the broad range of conditions
GPs treat do not allow them to review satisfactorily all
relevant professional information—in itself time consum-
ing and not always sufficiently convincing or technically
clear. Although SPs rely on professional information more
than GPs, they too make regular use of commercial infor-
mation. For both SPs and GPs, sales representatives are
often the first source of information, as well as an expe-
dient means of keeping up-to-date and of acquiring
and processing new drug-related information—even
when doctors set to minimise the importance of sales
representatives, to avoid distorted, selective, and overly
positive information [47,49]. Many interview-based stud-
ies— Prosser, Almond and Walley [49], Avorn, Chen, and
Hartley [83], and M. Y. Peay and E. R. Peay [84], for
example, all excluded from this review—confirmed the
prominence of commercial information in early adoption
of new drugs. Interactions with sales representatives had
a particularly strong impact [8,43,49,50,72,84]—early pre-
scribers used sales representatives intensively [49,72].
eGarcía et al. [24] used drug expenditure as proxy for
prescribing volume.
fThese studies [55-61] were deemed ineligible because
they did not meet all eligibility criteria. Azoulay [55],
Berndt et al. [56], Cleary [57], and Lilien et al. [58] did
not include any prescriber or practice characteristic;
Gönül et al. [59] did not disclose anything about the na-
ture of the drugs (new or old); the prescribing volume
in Manchanda and Chintagunta [60] was indicative of
old rather than new drugs; and Manchanda et al. [61]
focused on the effectiveness of sales calls rather than the
evaluation of factors affecting new drug uptake.gThese studies [62-67] were deemed ineligible because
they did not meet the third eligibility criterion.
hDespite the unavailability of registry-based prescrip-
tion data at the time, this study [7] was deemed eligible
because it did meet the eligibility criteria—prescription
data had been collected from pharmacies, rendering the
analysis exempt from recall bias.
iGlass and Dalton [30] and Liu and Gupta [13] only
had proxies for marketing spending. Glass and Dalton
[30] included pharmaceutical company revenue as input
variable, on the assumptions that larger companies had
more marketing and sales resources for supporting clin-
ical trials and selecting investigators, as well as for main-
taining contact both during and after clinical trials. In a
similar vein, Liu and Gupta [13] included journal adver-
tising expenditure as input variable.
jSupply- and demand-size measures do not qualify
for being quantitatively measurable predictors of new
drug uptake—the reason why these measures were
note reviewed in this article systematically.
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